Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has a beta value of 1.01 and has seen 1.19 million shares traded in the last trading session. The company, currently valued at $1.42B, closed the last trade at $14.11 per share which meant it gained $1.32 on the day or 10.32% during that session. The RCKT stock price is -130.55% off its 52-week high price of $32.53 and 10.56% above the 52-week low of $12.62. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.2 million shares traded. The 3-month trading volume is 902.34K shares.
The consensus among analysts is that Rocket Pharmaceuticals Inc (RCKT) is Buy stock at the moment, with a recommendation rating of 1.13. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.74.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) trade information
Sporting 10.32% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RCKT stock price touched $14.11 or saw a rise of 0.98%. Year-to-date, Rocket Pharmaceuticals Inc shares have moved -52.92%, while the 5-day performance has seen it change 0.93%. Over the past 30 days, the shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) have changed -18.06%. Short interest in the company has seen 11.9 million shares shorted with days to cover at 14.81.
Wall Street analysts have a consensus price target for the stock at $39, which means that the shares’ value could jump 63.82% from current levels. The projected low price target is $34.0 while the price target rests at a high of $69.0. In that case, then, we find that the current price level is -389.01% off the targeted high while a plunge would see the stock gain -140.96% from current levels.
Rocket Pharmaceuticals Inc (RCKT) estimates and forecasts
Figures show that Rocket Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -34.13% over the past 6 months, with this year growth rate of 2.40%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
9 analysts offering their estimates for the company have set an average revenue estimate of 34.78k for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -9.09% over the past 5 years. Earnings growth for 2024 is a modest 2.49% while over the next 5 years, the company’s earnings are expected to increase by 41.70%.
RCKT Dividends
Rocket Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT)’s Major holders
Insiders own 3.40% of the company shares, while shares held by institutions stand at 106.98% with a share float percentage of 110.75%. Investors are also buoyed by the number of investors in a company, with Rocket Pharmaceuticals Inc having a total of 289.0 institutions that hold shares in the company. The top two institutional holders are RTW INVESTMENTS, LP with over 17.69 million shares worth more than $380.82 million. As of 2024-06-30, RTW INVESTMENTS, LP held 18.8677% of shares outstanding.
The other major institutional holder is WELLINGTON MANAGEMENT GROUP LLP, with the holding of over 9.16 million shares as of 2024-06-30. The firm’s total holdings are worth over $197.12 million and represent 9.7665% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund . As of Jul 31, 2024 , the former fund manager holds about 7.12% shares in the company for having 6.49 shares of worth $91.58 million while later fund manager owns 2.46 shares of worth $34.72 million as of Jun 30, 2024 , which makes it owner of about 2.70% of company’s outstanding stock.
